Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Q1 2025 Earnings Call Transcript May 6, 2025 Dynavax Technologies Corporation misses on earnings expectations. Reported EPS is $0.01 EPS, expectations were $0.03. Operator: Good day ladies and ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent ...

These are still high on the list of AZ’s core focus today ... this time to develop small-molecule protein kinase B (PKB) to further contribute in the fight against cancer.

Objective Hepatitis B virus (HBV) can integrate into the chromosomes of infected ... Immunohistochemistry was performed to evaluate the expression of HBsAg and HBV core antigen. Intrahepatic ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Background Hepatitis B virus (HBV) is a common cause of viral ... to HBsAg testing and also to ascertain likely cause of weakly positive (grayzone) results. Results During the 17 month study ...

Discover an awarding winning abstract from EASL 2025 that has called for more person-centred hepatitis screening. Learn more.

Spontaneous loss of hepatitis ... B. Objectives: Upon completion of this article the reader will be able to choose the optimal drug regimen and timing of therapy for a patient with HBeAg-positive ...

Different clients, same surface level OCD symptoms. But underneath? Totally different fears. Discover why identifying the ...